- By insider
CEO & President of Intercept Pharmaceuticals Inc (ICPT) Mark Pruzanski sold 40,000 shares of ICPT on 06/26/2017 at an average price of $130.8 a share. The total sale was $5.2 million.
Intercept Pharmaceuticals Inc is a biopharmaceutical company. The Company is engaged in the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases with unmet medical need utilizing its bile acid chemistry. Intercept Pharmaceuticals Inc has a market cap of $3.08 billion; its shares were traded at around $122.99 with and P/S ratio of 67.06. Intercept Pharmaceuticals Inc had annual average EBITDA growth of 41.70% over the past five years.
-
Warning! GuruFocus has detected 3 Warning Signs with ICPT. Click here to check it out.
-
The intrinsic value of ICPT
CEO Recent Trades:
-
CEO & President Mark Pruzanski sold 40,000 shares of ICPT stock on 06/26/2017 at the average price of $130.8. The price of the stock has decreased by 5.97% since.
Directors and Officers Recent Trades:
-
President International Lisa Bright sold 698 shares of ICPT stock on 06/01/2017 at the average price of $110.73. The price of the stock has increased by 11.07% since.
For the complete insider trading history of ICPT, click here
.This article first appeared on GuruFocus.
-
Warning! GuruFocus has detected 3 Warning Signs with ICPT. Click here to check it out.
-
The intrinsic value of ICPT